Literature DB >> 27318442

Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.

Yang O Huh1, Guilin Tang2, Sameer S Talwalkar2, Joseph D Khoury2, Maro Ohanian3, Carlos E Bueso-Ramos2, Lynne V Abruzzo4.   

Abstract

Double minute chromosomes (dmin) are small, paired chromatin bodies that lack a centromere and represent a form of extrachromosomal gene amplification. Dmin are rare in myeloid neoplasms and are generally associated with a poor prognosis. Most studies of dmin in myeloid neoplasms are case reports or small series. In the current study, we present the clinicopathologic and cytogenetic features of 22 patients with myeloid neoplasms harboring dmin. These neoplasms included acute myeloid leukemia (AML) (n = 18), myelodysplastic syndrome (MDS) (n = 3), and chronic myelomonocytic leukemia (CMML) (n = 1). The AML cases consisted of AML with myelodysplasia-related changes (n = 13) and therapy-related AML (n = 5). Dmin were detected in initial pre-therapy samples in 14 patients with AML or CMML; they were acquired during the disease course in 8 patients who had AML or MDS. The presence of dmin was associated with micronuclei (18/18; 100%), complex karyotype (17/22; 77.3%), and amplification of MYC (12/16; 75%) or MLL (4/16; 25%). Immunohistochemical staining for MYC performed on bone marrow core biopsy or clot sections revealed increased MYC protein in all 19 cases tested. Except for one patient, most patients failed to respond to risk-adapted chemotherapies. At last follow up, all patients had died of disease after a median of 5 months following dmin detection. In conclusion, dmin in myeloid neoplasms commonly harbor MYC or MLL gene amplification and manifest as micronuclei within leukemic blasts. Dmin are often associated with myelodysplasia or therapy-related disease, and complex karyotypes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Double minute chromosomes; MLL; MYC; acute myeloid leukemia; micronuclei; myelodysplastic syndrome

Mesh:

Substances:

Year:  2016        PMID: 27318442     DOI: 10.1016/j.cancergen.2016.05.072

Source DB:  PubMed          Journal:  Cancer Genet


  13 in total

1.  Megakaryoblastic transformation of therapy-related myeloid neoplasms with concomitant MYC amplification on double minute chromosomes.

Authors:  Katsuya Yamamoto; Kimikazu Yakushijin; Yumiko Inui; Shinichiro Kawamoto; Kazuyoshi Kajimoto; Yoshitake Hayashi; Hiroshi Matsuoka; Hironobu Minami
Journal:  Int J Hematol       Date:  2017-09-07       Impact factor: 2.490

Review 2.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

3.  MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Authors:  Maro Ohanian; Uri Rozovski; Rashmi Kanagal-Shamanna; Lynne V Abruzzo; Sanam Loghavi; Tapan Kadia; Andrew Futreal; Kapil Bhalla; Zhuang Zuo; Yang O Huh; Sean M Post; Peter Ruvolo; Guillermo Garcia-Manero; Michael Andreeff; Steven Kornblau; Gautam Borthakur; Peter Hu; L Jeffrey Medeiros; Koichi Takahashi; Marisa J Hornbaker; Jianhua Zhang; Graciela M Nogueras-González; Xuelin Huang; Srdan Verstovsek; Zeev Estrov; Sherry Pierce; Farhad Ravandi; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jorge E Cortes
Journal:  Leuk Lymphoma       Date:  2018-05-09

4.  FLT3 Amplification as Double Minute Chromosomes in a Patient with Chronic Myelomonocytic Leukemia.

Authors:  Heyang Zhang; Xiaoxue Wang; Shibo Li; Xianfu Wang; Xianglan Lu; Ming Li; Hua Wang; Ying Liu; Hui Pang; Lijun Zhang
Journal:  Dis Markers       Date:  2021-06-05       Impact factor: 3.434

5.  MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

Authors:  Alberto L Abbate; Doron Tolomeo; Ingrid Cifola; Marco Severgnini; Antonella Turchiano; Bartolomeo Augello; Gabriella Squeo; Pietro D Addabbo; Debora Traversa; Giulia Daniele; Angelo Lonoce; Mariella Pafundi; Massimo Carella; Orazio Palumbo; Anna Dolnik; Dominique Muehlematter; Jacqueline Schoumans; Nadine Van Roy; Gianluca De Bellis; Giovanni Martinelli; Giuseppe Merla; Lars Bullinger; Claudia Haferlach; Clelia Tiziana Storlazzi
Journal:  Leukemia       Date:  2018-02-22       Impact factor: 11.528

6.  Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.

Authors:  Mohammad Shahjahani; Elham Homaei Hadad; Shirin Azizidoost; Kowsar Chenani Nezhad; Saeid Shahrabi
Journal:  Oncol Rev       Date:  2019-02-04

7.  [Amplification of Extrachromosomal Oncogene and Tumorigenesis and Development].

Authors:  Yutong Wang; Fan Ye; Xiao Zhang; Ruihan Zou; Mingyuan Wang; Kai Yu; Shiyun Cui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-12-20

Review 8.  Techniques for detecting chromosomal aberrations in myelodysplastic syndromes.

Authors:  Qibin Song; Min Peng; Yuxin Chu; Shiang Huang
Journal:  Oncotarget       Date:  2017-05-09

Review 9.  Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance.

Authors:  Yuanliang Yan; Guijie Guo; Jinzhou Huang; Ming Gao; Qian Zhu; Shuangshuang Zeng; Zhicheng Gong; Zhijie Xu
Journal:  J Hematol Oncol       Date:  2020-09-14       Impact factor: 17.388

Review 10.  Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.

Authors:  Xiang Gu; Jie Yu; Peiwei Chai; Shengfang Ge; Xianqun Fan
Journal:  J Exp Clin Cancer Res       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.